EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Apical myocardial fibrosis burden identifies a high-risk phenotype and predicts cardiac mortality after LVAD implantation

İbrahim Demir iD, Bilge Ecemiş iD, Ayşe Zorba iD, Işık İkbal Barış iD, Berhan Keskin iD, Emir Cantürk iD, Yahya Yıldız iD, İbrahim Oğuz Karaca iD, Korhan Erkanlı iD

ESC Heart Failure · 05.05.2026 · 13 (3)

DOI: 10.1093/eschf/xvag135 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESC Heart Failure, online erschienen am 12.05.2026. Verfasst von İbrahim Demir und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery, Istanbul Medipol University, Istanbul 34214, Turkey. Hauptthemen laut MEDLINE: Heart-Assist Devices, Heart Failure, Myocardium, Ventricular Remodeling. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Advanced heart failure is characterized by progressive myocardial remodelling, with fibrosis representing a final common pathway of chronic injury. We investigated whether quantitatively assessed apical myocardial fibrosis burden at the time of left ventricular assist device (LVAD) implantation is associated with overall and cause-specific mortality.

Methods

This single-centre retrospective cohort study included 47 consecutive patients undergoing durable LVAD implantation between 2019 and 2025. Median age was 63 years and 14.9% were female. Myocardial tissue obtained from the left ventricular apical core at implantation was analysed using structured histopathologic scoring (THS-10) and quantitative digital morphometry (QuPath). Fibrosis burden was quantified as collagen-positive area relative to total myocardial area. Overall survival was assessed using Kaplan–Meier analysis and Cox regression. Cardiac mortality was evaluated using Fine–Gray competing-risk models, with non-cardiac death treated as a competing event.

Results

Median follow-up was 1513 days. During follow-up, 27 deaths occurred (57.4%), including 16 cardiovascular and 11 non-cardiac deaths. Quantitative fibrosis burden showed a strong unadjusted association with overall survival (log-rank P = .00042). Receiver operating characteristic (ROC) analysis identified a cohort-derived fibrosis threshold of 33.7% for overall mortality risk stratification (area under the curve [AUC] 0.739, 95% confidence interval [CI] 0.566–0.912). In univariable Cox analysis, fibrosis burden and THS-10 score were associated with mortality (hazard ratio [HR] 39.39, 95% CI 2.61–594.56, P = .008; and HR 1.51, 95% CI 1.14–2.01, P = .005, respectively). After multivariable adjustment for clinical severity, including INTERMACS profile and key laboratory parameters, the association with all-cause mortality was attenuated. In competing-risk analysis, high fibrosis burden independently predicted cardiac mortality (subdistribution HR approximately 4.1, P = .02). Additional exploratory ROC analysis for cardiovascular death showed an AUC of 0.752, with a cohort-derived threshold of 39.6%.

Conclusion

Quantitatively assessed apical myocardial fibrosis burden identifies a biologically high-risk myocardial phenotype in LVAD recipients. While the association with all-cause mortality is attenuated after adjustment, fibrosis burden shows a specific relationship with cardiac mortality when competing non-cardiac risk is taken into account. These findings support the prognostic relevance of myocardial substrate and warrant external validation in larger prospective cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart-Assist DevicesHeart FailureMyocardiumVentricular RemodelingHeart VentriclesCardiomyopathiesHumansFemaleRetrospective StudiesFibrosisMiddle AgedMalePhenotypeFollow-Up StudiesSurvival RateRisk AssessmentPrognosisRisk FactorsAged

Stichwörter der Autor:innen

Heart failureHistopathologyLeft ventricular assist deviceMyocardial fibrosis

Autor:innen und Institutionen

  • Department of Cardiovascular Surgery, Istanbul Medipol University, Istanbul 34214, Turkey.
  • Department of Pathology, Istanbul Medipol University, Istanbul 34214, Turkey.
  • Department of Cardiology, Istanbul Medipol University, Istanbul 34214, Turkey.
  • Department of Anesthesiology and Reanimation, Istanbul Medipol University, Istanbul 34214, Turkey.

ORCID-Profile: İbrahim Demir, Bilge Ecemiş, Ayşe Zorba, Işık İkbal Barış, Berhan Keskin, Emir Cantürk, Yahya Yıldız, İbrahim Oğuz Karaca, Korhan Erkanlı

Zitieren

APA

Demir, İ., Ecemiş, B., Zorba, A., Barış, I. İ., Keskin, B., Cantürk, E., Yıldız, Y., Karaca, İ. O., & Erkanlı, K. (2026). Apical myocardial fibrosis burden identifies a high-risk phenotype and predicts cardiac mortality after LVAD implantation. ESC Heart Failure, 13(3). https://doi.org/10.1093/eschf/xvag135

Vancouver

Demir İ, Ecemiş B, Zorba A, Barış Iİ, Keskin B, Cantürk E, et al. Apical myocardial fibrosis burden identifies a high-risk phenotype and predicts cardiac mortality after LVAD implantation. ESC Heart Failure. 2026;13(3). doi:10.1093/eschf/xvag135

BibTeX
@article{Demir2026,
  author = {Demir, İbrahim and Ecemiş, Bilge and Zorba, Ayşe and Barış, Işık İkbal and Keskin, Berhan and Cantürk, Emir and Yıldız, Yahya and Karaca, İbrahim Oğuz and Erkanlı, Korhan},
  title = {Apical myocardial fibrosis burden identifies a high-risk phenotype and predicts cardiac mortality after LVAD implantation},
  journal = {ESC Heart Failure},
  year = {2026},
  volume = {13},
  number = {3},
  doi = {10.1093/eschf/xvag135}
}
Kostenlos starten →